The COVID-19 Textbook


CHAPTER 15 • Treatment of COVID-19 in Adults

REFERENCES 1. Kalil AC. Treating COVID-19-off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA . 2020;323:1897-1898. 2. Siedner MJ, Gandhi RT, Kim AY. Desperate times call for temperate measures: practicing infectious diseases during a novel pandemic. J Infect Dis . 2020;222:1084-1085. 3. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA . 2020;323:1239-1242. 4. COVID-19 Treatment Guidelines Panel. Coronavirus 2019 (COVID-19) treatment guidelines. National Institutes of Health. Accessed January 27, 2023. 5. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med . 2020;382:1708-1720. 6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet . 2020;395:497-506. 7. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet . 2020;395:1054-1062. 8. Flythe JE, Assimon MM, Tugman MJ, et al. Characteristics and outcomes of individuals with pre-existing kidney disease and COVID-19 admitted to intensive care units in the United States. Am J Kidney Dis . 2021;77:190-203.e1. 9. COVIDSurg Collaborative. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. Lancet . 2020;396:27-38. 10. Varner CE. In adults, NSAID use vs. nonuse in the past 4 mo was not linked to increased risk for COVID-19-related mortality. Ann Intern Med . 2021;174:JC58. 11. Zhao H, Huang S, Huang S, et al. Prevalence of NSAID use among people with COVID-19 and the association with COVID-19-related outcomes: systematic review and meta-analysis. Br J Clin Pharmacol . 2022;88:5113-5127. 12. Gandhi RT. The multidimensional challenge of treating coronavirus disease 2019 (COVID-19): remdesivir is a foot in the door. Clin Infect Dis . 2021;73:e4175-e4178. 13. Gandhi RT, Lynch JB, Del Rio C. Mild or moderate Covid-19. N Engl J Med . 2020;383:1757-1766. 14. Centers for Disease Control and Prevention. Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare professionals. Accessed January 27, 2023. 15. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med . 2022;386:509-520. 16. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med . 2022; 386:1397-1408. 17. Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to prevent progression to severe Covid-19 in outpatients. N Engl J Med . 2022;386:305-315. 18. Gandhi RT, Malani PN, Del Rio C. COVID-19 therapeutics for nonhospitalized patients. JAMA . 2022;327:617-618. 19. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19—final report. N Engl J Med . 2020;383:1813-1826. 20. Group RC, Horby P, Lim WS, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med . 2021;384:693-704. 21. Kalil AC, Patterson TF, Mehta AK, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med . 2021;384:795-807. 22. WHO Solidarity Trial Consortium. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses. Lancet . 2022;399:1941-1953. 23. Spinner CD, Gottlieb RL, Criner GJ, et al. Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial. JAMA . 2020;324:1048-1057. 24. Morris SB, Schwartz NG, Patel P, et al. Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection—United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep . 2020;69:1450-1456. 25. Shankaranarayanan D, Muthukumar T, Barbar T, et al. Anticoagulation strategies and filter life in COVID-19 patients receiving continuous renal replacement therapy: a single-center experience. Clin J Am Soc Nephrol . 2020;16:124-126. 26. ATTACC Investigators; ACTIV-4a Investigators; REMAP-CAP Investigators, et al. Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med . 2021;385:790-802. 27. Sholzberg M, Tang GH, Rahhal H, et al. Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ . 2021;375:n2400. 28. INSPIRATION Investigators; Sadeghipour P, Talasaz AH, Rashidi F, et al. Effect of intermediate-dose vs standard-dose prophylactic anticoagulation on thrombotic events, extracorporeal membrane oxygenation treatment, or mortality among patients with COVID-19 admitted to the intensive care unit: the INSPIRATION randomized clinical trial. JAMA . 2021;325:1620-1630. 29. REMAP-CAP Investigators; ACTIV-4a Investigators; ATTACC Investigators, et al. Therapeutic anticoagulation with heparin in critically ill patients with Covid-19. N Engl J Med . 2021;385:777-789.

Copyright © 2023 Wolters Kluwer, Inc. Unauthorized reproduction of the content is prohibited.

Made with FlippingBook - professional solution for displaying marketing and sales documents online